PeptidesCategoriesResearch

Thymosin Beta-4

A 43-amino acid peptide that is the major actin-sequestering molecule in mammalian cells, playing critical roles in tissue repair, wound healing, angiogenesis, and anti-inflammatory signaling.

Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.

Mechanism of Action

Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.

Safety Profile

Safety Profile: Thymosin Beta-4 (TB-4 / TB-500)

Common Side Effects

  • Injection site reactions including pain, redness, swelling, and bruising (subcutaneous or intramuscular administration)
  • Headache and mild fatigue during initial dosing
  • Mild nausea reported in some users
  • Transient flu-like symptoms (low-grade fever, malaise) due to immune modulation
  • Mild dizziness and lightheadedness

Serious Adverse Effects

  • Cancer concerns: Thymosin beta-4 promotes angiogenesis and cell migration; theoretical risk of promoting tumor growth or metastasis in individuals with existing cancers; animal studies show conflicting results
  • Limited controlled human safety data; most evidence from animal studies and anecdotal reports
  • Potential for immune dysregulation with chronic use; may either stimulate or suppress immune pathways depending on context
  • Rare allergic reactions including systemic hypersensitivity
  • No significant organ toxicity (hepatic, renal, cardiac) reported in available clinical data, but long-term safety is unestablished

Contraindications

  • Known or suspected malignancy (due to pro-angiogenic and cell migration properties)
  • Known hypersensitivity to thymosin beta-4 or related peptides
  • Active infections that may worsen with immune modulation
  • Pregnancy and lactation (no reproductive safety data)
  • Recent history of cancer (within 5 years) without oncologist clearance

Drug Interactions

  • Immunosuppressants: May interfere with or counteract immunosuppressive therapy
  • Anti-angiogenic cancer therapies (bevacizumab, sunitinib): Directly opposes the mechanism of these drugs; strictly contraindicated
  • Growth hormone and other growth factors (IGF-1, BPC-157): Additive proliferative and angiogenic effects; monitor for excessive tissue response
  • Corticosteroids: Complex interaction; TB-4 may partially counteract anti-inflammatory effects while steroids may blunt TB-4's tissue repair actions
  • Anticoagulants: No direct interaction established, but injection-related bruising may be more pronounced

Population-Specific Considerations

  • Athletes: Frequently used for injury recovery; prohibited by WADA under S2 (peptide hormones, growth factors); not legal for competitive athletes
  • Elderly: Potentially beneficial for wound healing and tissue repair; use with caution given theoretical cancer risk
  • Pediatric: No safety data; not recommended
  • Cancer survivors: Avoid due to pro-angiogenic properties unless specifically cleared by oncologist
  • Post-surgical patients: Potential benefit for wound healing, but not FDA-approved for this indication; investigational use only

Pharmacokinetic Profile

Half-life
Dose-dependent; relatively short (exact values not established)

Quick Start

Typical Dose
2-6mg per injection (varies by protocol and severity)
Frequency
Daily for acute healing, 2x weekly for maintenance/chronic conditions
Route
Subcutaneous injection
Cycle Length
2-12 weeks depending on healing needs
Storage
Reconstituted: 2-8°C, use within 14 days

Molecular Structure

2D Structure
Thymosin Beta-4 molecular structure
Molecular Properties
Formula
C212H350N56O78S
Weight
4 Da
Length
43 amino acids
PubChem CID
45382195
Exact Mass
4962.4930 Da
LogP
-43.5
TPSA
2250 Ų
H-Bond Donors
72
H-Bond Acceptors
88
Rotatable Bonds
180
Complexity
12200
Identifiers (SMILES, InChI)
InChI
InChI=1S/C212H350N56O78S/c1-16-106(7)166(261-190(323)131(64-75-160(292)293)231-172(305)109(10)228-174(307)134(78-91-347-15)245-196(329)140(98-165(302)303)255-201(334)147-53-39-88-266(147)209(342)135(52-29-38-87-221)250-197(330)139(97-164(300)301)254-198(331)143(100-269)229-113(14)276)204(337)246-129(62-73-158(288)289)187(320)233-118(47-24-33-82-216)179(312)252-137(94-114-42-19-18-20-43-114)194(327)253-138(96-163(298)299)195(328)237-121(50-27-36-85-219)181(314)258-144(101-270)199(332)239-119(48-25-34-83-217)178(311)251-136(92-104(3)4)193(326)236-116(45-22-31-80-214)175(308)235-122(51-28-37-86-220)189(322)263-168(110(11)273)207(340)249-133(66-77-162(296)297)192(325)264-169(111(12)274)206(339)248-126(58-69-152(224)279)184(317)243-128(61-72-157(286)287)186(319)234-120(49-26-35-84-218)180(313)256-142(95-153(225)280)211(344)268-90-40-54-148(268)202(335)257-141(93-105(5)6)210(343)267-89-41-55-149(267)203(336)259-145(102-271)200(333)238-117(46-23-32-81-215)177(310)244-132(65-76-161(294)295)191(324)265-170(112(13)275)208(341)262-167(107(8)17-2)205(338)247-130(63-74-159(290)291)188(321)241-125(57-68-151(223)278)183(316)242-127(60-71-156(284)285)185(318)232-115(44-21-30-79-213)176(309)240-124(56-67-150(222)277)173(306)227-108(9)171(304)226-99-154(281)230-123(59-70-155(282)283)182(315)260-146(103-272)212(345)346/h18-20,42-43,104-112,115-149,166-170,269-275H,16-17,21-41,44-103,213-221H2,1-15H3,(H2,222,277)(H2,223,278)(H2,224,279)(H2,225,280)(H,226,304)(H,227,306)(H,228,307)(H,229,276)(H,230,281)(H,231,305)(H,232,318)(H,233,320)(H,234,319)(H,235,308)(H,236,326)(H,237,328)(H,238,333)(H,239,332)(H,240,309)(H,241,321)(H,242,316)(H,243,317)(H,244,310)(H,245,329)(H,246,337)(H,247,338)(H,248,339)(H,249,340)(H,250,330)(H,251,311)(H,252,312)(H,253,327)(H,254,331)(H,255,334)(H,256,313)(H,257,335)(H,258,314)(H,259,336)(H,260,315)(H,261,323)(H,262,341)(H,263,322)(H,264,325)(H,265,324)(H,282,283)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)(H,294,295)(H,296,297)(H,298,299)(H,300,301)(H,302,303)(H,345,346)
InChIKeyUGPMCIBIHRSCBV-UHFFFAOYSA-N

Research Indications

Tissue Repair

Strong Evidence
Wound Healing Acceleration

Clinical trials show 67% complete healing versus 25% placebo in pressure ulcers.

Strong Evidence
Post-Surgical Recovery

Enhanced tissue regeneration and reduced healing time in surgical wounds.

Strong Evidence
Soft Tissue Injury Repair

Accelerated recovery in muscle, tendon, and ligament injuries.

Cardiovascular

Good Evidence
Cardiac Protection Post-MI

Phase 2b trials show 43% reduction in infarct size when given within 6 hours.

Good Evidence
Coronary Artery Disease

Improved cardiac function and reduced adverse remodeling.

Good Evidence
Peripheral Vascular Disease

Enhanced angiogenesis and improved blood flow to affected tissues.

Neuroprotection

Moderate Evidence
Stroke Recovery Enhancement

Improved neurological outcomes and functional recovery in animal models.

Moderate Evidence
Traumatic Brain Injury

Reduced brain edema and enhanced neural repair mechanisms.

Moderate Evidence
Spinal Cord Injury Support

Neuroprotective effects and functional recovery promotion.

Research Protocols

subcutaneous Injection

Systemic regenerative effects with proven clinical efficacy and optimal bioavailability.

GoalDoseFrequency
Acute Wound Healing1.6mgDaily
Cardiac Protection42mgSingle dose
Chronic Tissue Repair6mgTwice weekly
Neurological Recovery30mgThree times over 72 hours
General Regeneration2-5mgDaily or every other day
Reconstitution Guide (mg vial + mL BAC water)
  1. Allow lyophilized powder to reach room temperature before reconstitution
  2. Add bacteriostatic water slowly to vial wall, avoiding direct powder contact
  3. Gently swirl (do not shake vigorously) until completely dissolved
  4. Inspect solution for clarity—should be clear and colorless
  5. Store reconstituted solution at 2-8°C and use within 14 days
  6. Use proper aseptic technique and rotate injection sites

topical

Direct wound application with proven corneal healing and minimal systemic exposure.

GoalDoseFrequency
Pressure Ulcer Healing1% gelOnce daily
Corneal Healing0.1% drops4 times daily
Chronic Wound Care0.5% creamTwice daily

Interactions

Peptide Interactions

✦
TB-500synergistic

TB-500 is the bioactive fragment of Thymosin β4. Combined use provides full-length peptide benefits plus concentrated bioactive effects.

✦
BPC-157synergistic

Complementary healing mechanisms—Tβ4 promotes cell migration and angiogenesis while BPC-157 enhances gastric protection.

✓
IGF-1compatible

Complementary growth factor effects without direct interaction.

What to Expect

What to Expect

Week 1-2

Initial tissue response, possible mild injection site reactions

Week 2-4

Accelerated healing becomes apparent, reduced inflammation

Week 4-8

Significant tissue regeneration and functional improvement

Week 8-12

Sustained benefits and near-complete healing in responsive conditions

Safety Profile

Common Side Effects

  • Mild injection site reactions
  • Local inflammation at injection sites

Contraindications

  • Active chemotherapy treatment
  • Severe systemic allergies to peptides

Discontinue If

  • Severe injection site reactions or persistent inflammation
  • Signs of systemic allergic reaction (rash, breathing difficulty)
  • Unexpected cardiovascular symptoms during treatment
  • Any signs of infection at injection sites

Quality Indicators

What to look for

  • Clear, colorless solution when reconstituted
  • Proper sterile packaging with intact seals
  • Certificate of analysis showing >98% purity
  • Appropriate molecular weight confirmed via HPLC/MS

Caution

  • Room temperature storage claims—legitimate product requires refrigeration after reconstitution

Red flags

  • Cloudy or discolored solution indicating degradation
  • Crystallization after reconstitution suggesting improper storage

References (4)

  1. [1]
    Phase II Dry Eye Clinical Trial (2015)
  2. [2]
    Phase I Human Safety Study: Intravenous Thymosin β4 (2010)
  3. [3]
    Cardiac Protection Pilot Study: Thymosin β4 in STEMI Patients (2016)
  4. [4]
    Neurotrophic Keratopathy Compassionate Use Trial (2010)
Updated 2026-03-08Sources: jabronistore-wiki, pep-pedia, pubchem

On this page

Mechanism of Action
Safety Profile
Pharmacokinetic Profile
Quick Start
Molecular Structure
Research Indications
Research Protocols
Interactions
What to Expect
Safety Profile
Quality Indicators
References